Welcome to our dedicated page for Alaunos Therapeutics news (Ticker: TCRT), a resource for investors and traders seeking the latest updates and insights on Alaunos Therapeutics stock.
Alaunos Therapeutics, Inc. (TCRT) reports developments as an early-stage biotechnology company focused on orally administered small-molecule therapeutics for obesity and related metabolic disorders. Recent updates center on ALN1003, a non-hormonal, non-incretin oral candidate evaluated in preclinical diet-induced obesity models, including body-weight, liver and metabolic biomarker findings.
Company news also reflects Alaunos's transition from earlier TCR-T cell therapy programs for solid tumors, including the TCR-T Library trial, the Sleeping Beauty cell engineering platform and the hunTR discovery platform. Recurring corporate updates include operating results, research spending, capital-structure actions, Nasdaq listing compliance and governance changes.
CellChorus Inc. has established a scientific advisory board featuring experts Rebecca Berdeaux, PhD, Dimitrios Kontoyiannis, MD, PhD, and Laurence Cooper, MD, PhD. This board aims to promote the application of the company’s TIMING™ platform in various therapeutic areas, enhancing patient care. Dr. Berdeaux emphasizes the significance of single-cell analysis, while Dr. Cooper brings leadership experience from Alaunos Therapeutics and MD Anderson Cancer Center. The advisory board is expected to support CellChorus in expanding into new clinical applications.
Alaunos Therapeutics (TCRT) announces its participation in the Jefferies 2022 Global Healthcare Conference. The event is scheduled for June 10, 2022, from 9:00-9:25 am ET at the New York Marriott Marquis, Track 6. CEO Kevin S. Boyle Sr. and VP of R&D Drew Deniger, Ph.D. will present. A live webcast will be available on the company's website, with a replay accessible for 90 days post-event. Alaunos focuses on oncology cell therapies utilizing proprietary T-cell receptor technology, collaborating with leading institutes like MD Anderson and the National Cancer Institute.
Alaunos Therapeutics (TCRT) announced a Trials in Progress poster presentation at the 2022 ASCO Annual Meeting, scheduled from June 3-7, 2022. The presentation will cover the adaptive trial design for their ongoing TCR-T Library Phase 1/2 trial at MD Anderson Cancer Center, targeting various cancers with specific HLA and mutation pairings. The first patient has been dosed in the trial, which aims to utilize the company's proprietary Sleeping Beauty technology. Initial data is anticipated later this year as patient enrollment continues.
Alaunos Therapeutics (TCRT) announced the successful dosing of its first patient in the TCR-T Library Phase 1/2 trial targeting specific mutations in solid tumors. This milestone highlights the use of its proprietary non-viral TCR-T technology. The trial, conducted at MD Anderson Cancer Center, will evaluate safety and define dosage for patients with various cancers. Financially, Q1 2022 net loss decreased to $9.8 million from $21.6 million in Q1 2021, alongside a significant reduction in R&D and G&A expenses, attributed to cost-cutting measures. Cash reserves totaled $68.3 million, expected to last into Q2 2023.
Alaunos Therapeutics (Nasdaq: TCRT) will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, from 5:00-5:30 PM ET at the Fontainebleau Miami Beach Hotel. The presentation will be delivered by CEO Kevin S. Boyle Sr. and VP of R&D Drew Deniger, Ph.D. A live webcast will be available on the company's website, with replays accessible for 90 days. Alaunos focuses on T-cell receptor therapies for oncology, utilizing its proprietary Sleeping Beauty gene transfer technology and collaborating with leading cancer research institutions.
Alaunos Therapeutics (TCRT) is set to announce its financial results for the first quarter ending March 31, 2022, on May 16, 2022, before U.S. market opening. A conference call will follow at 8:30 a.m. ET to discuss the results and provide a corporate update. Interested parties can join via phone or live webcast, with the event archived for 30 days post-call. Alaunos focuses on developing T-cell receptor therapies using proprietary gene transfer technology, with collaborations with MD Anderson Cancer Center and the National Cancer Institute.
Alaunos Therapeutics has announced a poster presentation at the 25th Annual Meeting of the American Society of Gene and Cell Therapy, showcasing new preclinical data on its mbIL-15 program. This innovative cell therapy targets hotspot mutations in solid tumors, demonstrating enhanced survival capabilities. The research highlights the effectiveness of Sleeping Beauty transposed mbIL-15 TCR-T cells in improving clinical responses. The company plans to file an IND application for this program in H2 2023. The poster presentation is scheduled for May 16, 2022.
Alaunos Therapeutics has successfully dosed the first patient in its Phase 1/2 TCR-T Library trial targeting KRAS, TP53, and EGFR mutations in solid tumors. This milestone represents the first use of the company’s non-viral TCR-T cell therapy, manufactured in-house at its cGMP facility. The open-label study, conducted at MD Anderson Cancer Center, aims to determine the maximum tolerated dose and safety profile across various solid tumor types. Initial data is expected to be reported in the second half of 2022.
Alaunos Therapeutics, Inc. (TCRT) announced its fourth quarter and full year financial results for 2021, reporting a net loss of $11.8 million for Q4 and $78.8 million for the full year. Research and development expenses decreased to $8.2 million in Q4 from $14.0 million year-over-year. Significant milestones include the first patient consented in the Phase 1/2 TCR-T Library trial targeting solid tumors and an extended CRADA with the National Cancer Institute. As of December 31, 2021, the company had cash reserves of approximately $76.1 million.
Alaunos Therapeutics, Inc. (TCRT) will announce its fourth-quarter financial results for 2021 on March 30, 2022, before U.S. market open. Following this, a conference call and webcast will be held at 8:30 a.m. ET for a corporate update and financial review. Investors can access the call by dialing in or through a live webcast on the company’s website. Alaunos specializes in oncology-focused cell therapies, leveraging its Sleeping Beauty gene transfer platform, and has collaborations with notable institutions like MD Anderson Cancer Center and the National Cancer Institute.